miRNA Sequencing and Assay Market

Global miRNA Sequencing and Assay Market: Overview

Lately, miRNA sequencing and assay is gaining traction in the global miRNA sequencing and assay market. Rising number of research on genomics is likely to play a role in the expansion of the global miRNA and assay market during the forecast period 2018 to 2016.

An upcoming Transparency Market Research (TMR) report, shares precise insights on size, share, trend and growth factors of the global miRNA sequencing and assay market. This reports provides details on restraints, drivers, and notable development that has taken place in recent times in the global miRNA sequencing and assay market.

Global miRNA Sequencing and Assay Market: Notable Developments

Some notable developments in the area of miRNA sequencing and genomics are as follows.

• In June 2019, GeneNews announces that it has entered into a five year agreement with Oncore Pharma to conduct GeneNews colorectal cancer tests away from US and Canada. Oncore and its collaborators will commercialize ColonSentry diagnosis across the globe except US and Canada.

• In June 2019, Sweden based start-up Cartana entered into an agreement to incorporate its situ RNA sequencing technology with microfluidic processor technology of Lunaphore technologies. Together they are believed to create automating sequences and imaging process.

Some of the major players in the global miRNA sequencing and assay market include, Lexogen, Rosetta Genomics Ltd., HTG Molecular Diagnostics, Meridian Bioscience, Inc, New England Biolabs, Inc., Takara Bio Inc.,  QiagenN.V., and Thermo Fisher Scientific Inc.

Global miRNA Sequencing and Assay Market: Drivers & Restraints

Factors driving the global miRNA sequencing and assay market are as follows.

Technological advancement to augment miRNA Sequencing and Assay Market

Rising technological advancement in healthcare sector paves way for government to support genomics study by funding the research activities, this drives the global miRNA sequencing and assay market.  Moreover, prevalence of target oriented therapies increases the demand for sequencing and assay, thus, pushing the global miRNA sequencing and assay market to expand in the near future.

Additionally, rising occurrence of various types of cancer and complexities involved in diagnosis and treatment of certain types of cancer is projected to drive the global miRNA sequencing and assay market in the approaching years.

Increasing Neurological Diseases to Boost Growth

Genomics is gaining traction as a mainstream medicine due to its ability to identify disease and provide therapies based on genetics study. Over the year, there has been rise in the number of neurological disorder. This increases demand for customized medicines which need understanding of diseases at a molecular level. Thus, the global miRNA sequencing and assay market in the forthcoming years.

Unavailability of skilled professionals is likely to hinder the growth in the global miRNA sequencing and assay market during the forecast period.

Nevertheless, advanced technology in genomics and rising patient awareness on precision medicines are expected to drive the global miRNA sequencing and assay market towards a stellar growth in the upcoming years.

Global miRNA Sequencing and Assay Market: Geographical Analysis

The gobal miRNA sequencing and assay market is divided into five major regions , they are North America, South America, Europe, Asia Pacific, and Middle East and Africa. Among these, North America held the major share in the global miRNA sequencing and assay market in 2018. North America is projected to continue to dominate the global miRNA sequencing and assay market in the upcoming years. The growth in this region can be attributed to growing research activities in genomics and RNA biology.